Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
Published online by Cambridge University Press: 09 February 2024
Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Summary
Which of the following is associated with the greatest incidence of hyperprolactinemia?
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential PsychopharmacologyChildren and Adolescents, pp. 259 - 278Publisher: Cambridge University PressPrint publication year: 2023
References
Aman, M., Rettiganti, M., Nagaraja, H. N., et al. Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial. J Child Adolesc Psychopharmacol 2015; 25(6): 482–93. https://doi.org/10.1089/cap.2015.0005Google Scholar
Dominick, K. C., Wink, L. K., Pedapati, E. V., et al. Risperidone treatment for irritability in fragile X syndrome. J Child Adolesc Psychopharmacol 2018, 28(4): 274–78. https://doi.org/10.1089/cap.2017.0057Google Scholar
Erickson, C. A., Stigler, K. A., Wink, L. K., et al. A prospective open-label study of aripiprazole in fragile X syndrome. Psychopharmacology 2011; 216(1): 85–90. https://doi.org/10.1007/s00213-011-2194-7Google Scholar
Gotham, K., Pickles, A., Lord, C. Standardizing ADOS scores for a measure of severity in autism spectrum disorders. J Autism Develop Disord 2009; 39(5): 693–705. https://doi.org/10.1007/s10803-008-0674-3Google Scholar
Gotham, K., Risi, S., Pickles, A., Lord, C. The autism diagnostic observation schedule: revised algorithms for improved diagnostic validity. J Autism Develop Disord 2007; 37(4): 613–27. https://doi.org/10.1007/s10803-006-0280-1Google Scholar
Hersh, J. H., Saul, R. A. Health supervision for children with fragile X syndrome (clinical report). In Pediatric Clinical Practice Guidelines & Policies. Itasca, IL: American Academy of Pediatrics, 2021. https://doi.org/10.1542/9781581108224-health8_sub01Google Scholar
Kloosterboer, S. M., de Winter, B. C. M., Reichart, C. G., et al. Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder. Br J Clin Pharmacol 2021; 87(3): 1069–81. https://doi.org/10.1111/bcp.14465Google Scholar
Koch, M. T., Carlson, H. E., Kazimi, M. M., Correll, C. U. Antipsychotic-related prolactin levels and sexual dysfunction in mentally ill youth: a 3-month cohort study. J Am Acad Child Adolesc Psychiatry 2023; 15: S08908567(23)00125-9. doi: 10.1016/j.jaac.2023.03.007. Epub ahead of print. PMID: 36931560.Google Scholar
McCracken, J. T., McGough, J., Shah, B., et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347(5): 314–21. https://doi.org/10.1056/nejmoa013171Google Scholar
Muhle, R. A., Reed, H. E., Vo, L. C., et al. Clinical diagnostic genetic testing for individuals with developmental disorders. J Am Acad Child Adolesc Psychiatry 2017; 56(11): 910–13. https://doi.org/10.1016/j.jaac.2017.09.418Google Scholar
Savatt, J. M., Myers, S. M. Genetic testing in neurodevelopmental disorders. Front Pediatr 2021; 9. https://doi.org/10.3389/fped.2021.526779Google Scholar
Strawn, J. R., Geracioti, T. D. Editorial: a better perspective on antipsychotic-related hyperprolactinemia in children and adolescents. J Am Acad Child Adolesc Psychiatry 2023: S0890-8567(23)00240-X. doi: 10.1016/j.jaac.2023.05.003. Epub ahead of print. PMID: 37172820.Google Scholar